[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biogen Inc (BIIB)

Biogen Inc (BIIB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,890,088
  • Shares Outstanding, K 147,637
  • Annual Sales, $ 9,891 M
  • Annual Income, $ 1,293 M
  • EBIT $ 2,420 M
  • EBITDA $ 3,493 M
  • 60-Month Beta 0.16
  • Price/Sales 3.07
  • Price/Cash Flow 9.08
  • Price/Book 1.63

Options Overview Details

View History
  • Implied Volatility 36.06% (-0.08%)
  • Historical Volatility 47.69%
  • IV Percentile 58%
  • IV Rank 36.52%
  • IV High 50.85% on 10/16/25
  • IV Low 27.55% on 01/07/26
  • Expected Move (DTE 1) 4.18 (2.05%)
  • Put/Call Vol Ratio 0.59
  • Today's Volume 409
  • Volume Avg (30-Day) 1,805
  • Put/Call OI Ratio 0.86
  • Today's Open Interest 45,215
  • Open Int (30-Day) 50,367
  • Expected Range 200.17 to 208.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 34 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $2.96
  • Number of Estimates 16
  • High Estimate $4.28
  • Low Estimate $1.71
  • Prior Year $4.81
  • Growth Rate Est. (year over year) -38.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
186.02 +10.21%
on 07/15/26
219.01 -6.39%
on 07/02/26
-11.04 (-5.11%)
since 06/30/26
3-Month
184.90 +10.88%
on 06/02/26
219.72 -6.69%
on 06/29/26
+15.74 (+8.32%)
since 04/30/26
52-Week
124.56 +64.60%
on 08/01/25
219.72 -6.69%
on 06/29/26
+78.38 (+61.89%)
since 07/30/25

Most Recent Stories

More News
Biogen (NASDAQ:BIIB) Reports Upbeat Q2 CY2026

Biogen (NASDAQ:BIIB) Reports Upbeat Q2 CY2026

BIIB : 205.77 (-1.65%)
Can Biogen's Revenue Decline Finally Slow After Two Years of Contraction?

Barchart Research What to Expect from BIIB Earnings BIIB Generated July 28, 2026 Current Price $205.61 EPS Estimate $$1.09 Consensus Rating Moderate Buy Average Move 3.09% Can Biogen's Revenue Decline...

BIIB : 205.77 (-1.65%)
Biogen (BIIB) Reports Q2: Everything You Need To Know Ahead Of Earnings

Biogen (BIIB) Reports Q2: Everything You Need To Know Ahead Of Earnings

BIIB : 205.77 (-1.65%)
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine,...

STOK : 29.52 (+0.14%)
BIIB : 205.77 (-1.65%)
3 Profitable Stocks We Steer Clear Of

3 Profitable Stocks We Steer Clear Of

RVLV : 25.35 (-1.78%)
OCSL : 11.58 (-2.77%)
BIIB : 205.77 (-1.65%)
Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide

Virtual-first, multidisciplinary care model delivers care for adults living with ataxias, connecting them to expert neurologist options nationwide.

BIIB : 205.77 (-1.65%)
Biogen Appoints Michael J. Parini as Chief Legal Officer

CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. Parini will serve...

BIIB : 205.77 (-1.65%)
3 Reasons to Avoid BIIB and 1 Stock to Buy Instead

3 Reasons to Avoid BIIB and 1 Stock to Buy Instead

BIIB : 205.77 (-1.65%)
Stocks Settle Higher on Tame Inflation News

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.38%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.10%. September E-mini...

SNDK : 1,265.74 (+24.59%)
HL : 14.59 (+3.11%)
CDE : 15.16 (+3.62%)
TRI : 99.61 (-6.33%)
STX : 845.34 (+10.58%)
AMD : 487.26 (+13.43%)
SCCO : 183.01 (+4.30%)
SPY : 738.90 (+1.29%)
ADSK : 233.76 (-4.69%)
MU : 864.30 (+16.96%)
ORCL : 126.13 (+7.13%)
QQQ : 682.34 (+3.11%)
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment

Real-World Findings Support Long-Term Benefits of Continuous Treatment with LEQEMBI and Provide Important Insights into Treatment Experience Outside of a Clinical Trial Setting

BIIB : 205.77 (-1.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement...

See More

Key Turning Points

3rd Resistance Point 228.78
2nd Resistance Point 223.69
1st Resistance Point 216.46
Last Price 205.77
1st Support Level 204.13
2nd Support Level 199.04
3rd Support Level 191.81

See More

52-Week High 219.72
Last Price 205.77
Fibonacci 61.8% 183.37
Fibonacci 50% 172.14
Fibonacci 38.2% 160.91
52-Week Low 124.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.